Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach

Similar documents
11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives

Clostridium difficile Colitis

Running head: CLOSTRIDIUM DIFFICILE 1

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

The Epidemiology Of Clostridium Difficile Infections Among Oncology Patients

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018

Healthcare-associated Infections Annual Report December 2018

Enteric Clostridia 10/27/2011. C. perfringens: general. C. perfringens: Types & toxins. C. perfringens: Types & toxins

Enteric Clostridia. C. perfringens: general

Preventing Clostridium difficile Infection (CDI)

Learning Objectives 6/1/18

Clostridium Difficile Primer: Disease, Risk, & Mitigation

Clostridium difficile infection: The Present and the Future

Multi-Drug Resistant Organisms (MDRO)

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Clostridium difficile Infection: An Update on the Current State of Prevention

Clostridium difficile

Anaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci

Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist

Educational Module for Nursing Assistants in Long-term Care Facilities: Preventing and Managing Clostridium difficile Infections

Should we test Clostridium difficile for antimicrobial resistance? by author

Clostridium difficile: Review of Treatment & Prevention through Antimicrobial Stewardship

Policy for the Management of Clostridium Difficile

Clostridium difficile Infection Prevention. Basics of Infection Prevention 2-Day Mini-Course 2012

What bugs are keeping YOU up at night?

THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND

MICRO-ORGANISMS by COMPANY PROFILE

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

Microbiology : antimicrobial drugs. Sheet 11. Ali abualhija

Infection Control & Prevention

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

APPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.

VCH PHC SURGICAL PROPHYLAXIS RECOMMENDATIONS

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

Curricular Components for Infectious Diseases EPA

Principles of Antimicrobial therapy

Antimicrobial Resistance. The Case for Diagnostics to Better Direct Therapy

Objectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017

Georgia State University. Georgia State University. Zirka Thompson. Spring

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

General Approach to Infectious Diseases

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10

Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU

Aminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Preventing Clostridium difficile. July 13,

SESSION XVI NEW ANTIBIOTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Guideline Updates Change is Inevitable Especially in Infectious Diseases!

Author - Dr. Josie Traub-Dargatz

Antimicrobials & Resistance

CDI Management in Post-Acute Care: Part 1

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

Treatment of septic peritonitis

Clinical Spectrum of Disease. Clinical Features. Risk Factors. Risk of CDAD According to Antibiotic Class. Fluoroquinolones as Risk Factor for CDAD

GASTROINTESTINAL DISEASE IN THE HEALTHCARE SETTING: CLOSTRIDIUM DIFFICILE AND NOROVIRUS

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Surveillance of Multi-Drug Resistant Organisms

Clinical Practice Standard

Intra-abdominal Infections

Multidrug Resistant Organisms (MDROs) and Clostridium difficile (C. diff)

Source: Portland State University Population Research Center (

How your body decides if bacteria are friends or foes

** the doctor start the lecture with revising some information from the last one:

2010 ARO/CDI Prevalence Survey. MRSA [ ] VRE [ ] Clostridium difficile [ ]

Multi-drug resistant microorganisms

Course: Microbiology in Health and Disease

Nosocomial Antibiotic Resistant Organisms

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Course: Microbiology in Health and Disease Office Hours: Before or after Class or by appointment

SUMMARY OF PRODUCT CHARACTERISTICS

Standing Orders for the Treatment of Outpatient Peritonitis

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Healthcare-associated Infections Annual Report

Bacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number:

Meropenem for all? Midge Asogan ICU Fellow (also ID AT)

Resistant Infections: Superbugs and No Superdrugs

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

In-Service Training Program. Managing Drug-Resistant Organisms in Long-Term Care

Overview of Infection Control and Prevention

Standing Orders for the Treatment of Outpatient Peritonitis

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Infection control: Need for robust guidelines

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered

Antibiotic Prophylaxis Update

Hand washing, Asepsis, Precautions and Infection Control

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance

Healthcare-associated Infections Annual Report March 2015

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Enterobacter aerogenes

Antimicrobial Resistance

Antimicrobial Resistance Acquisition of Foreign DNA

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Antimicrobial Resistance

Transcription:

Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach

Historical overview The myriad causes of hospital acquired diarrhea Microbiology and ecology of Clostridium difficile Epidemiology Transmission of disease Pathogenesis Clinical manifestations of disease Diagnosis and differential diagnosis Principles of therapy Antibiotic Stewardship The role of alternative therapies Infection control issues

For unclear but probably several reasons, the incidence of disease is increasing dramatically Asymptomatic carriage of the organism is extremely common in hospitalized patients receiving antibiotics, and these patients usually do not become ill The vast majority of antibiotic associated diarrhea is not caused by Clostridium difficile Clostridium difficile forms spores that can survive for a long time in the environment No product that kills spores is safe to use on your hands

While mechanical dislodging with soap is the only way to deal with spores on your hands, we use antibacterial soap in order to kill the vegetative forms of the organism Diagnosis is no longer made by culture, rather an EIA of stool with sensitivity of only about 75% Once a positive test is obtained there is no reason to retest that patient, specifically there is no rationale for doing a test of persistence or test of cure Antimicrobial therapy frequently does not eradicate the organism from the stool, rather it reduces the amount and allows the normal flora to return. Isolation continues until diarrhea resolves.

22 year old female, patient of Dr. William Osler A miserable, emaciated creature in a wretched physical condition. Underwent surgical resection of a gastric tumor on August 26, 1892 Postoperatively developed diarrhea that became progressively more severe Died on post op day 15 Diphtheritic membrane

A fatal case of pseudo membranous colitis in 1948 was linked to streptomycin use, led to reexamination of the 1893 case. Myriads of gram positive cocci found- Staphylococcus aureus postulated as cause Studies in 1950 s and 60 s document an association but did not prove causation When C. difficile identified S. aureus research dries up S. aureus may still play a role in some cases of antibiotic associated diarrhea with or without pseudo membranes

Introduction of the lincosamide class of antimicrobials resulted in a significant increase in cases of pseudo membranous colitis, which was also called clindamycin colitis Seminal study by Tedesco in St. Louis 200 consecutive patients treated with clindamycin 42 developed diarrhea 20 had pseudo membranous colitis- alarming number S. aureus not found in these patients Extensive studies using the hamster model Generous support from Eli Lilly, the maker of clindamycin

Clostridium difficile is the major recognized cause but only accounts for about 15-20% of all cases Most causes unknown. Several candidates studied Candida species Clostridium perfringens Staphylococcus aureus Serendipitous infection by viruses, Salmonella, etc. Non-infectious changes in colonic fatty acid and carbohydrate metabolism induced by antibiotics

Clostridium difficile : the Organism

An anaerobic, spore forming gram positive rod first described as a member of the normal flora of healthy infants in 1935 Due to the difficulty in cultivating the organism it was originally called Bacillus difficilis. Given its current name 3 years later Closely related to C. sordellii but not to other toxigenic clostridia like C. perfringens, C. botulinum or C. tetani. Can be grown on selective media (CCFA)

Environmental Sources of C. difficile

Vegetative form Found in the gut, survives in the environment for 4-6 hours Susceptible to gastric acid, antibacterial soaps, alcohol based hand foams Neutralization of stomach acid with pantoprazole may allow the vegetative form to become pathogenic Spore form Found in the gut and in the environment Spore formation induced by stressing the organism: exposure to the environment, exposure to antimicrobials, sub lethal concentrations of microbicidal cleaning products Resistant to stomach acid, antibacterial soaps and alcohol based hand gels Can survive for a long time on surfaces

Vegetative vs. spore forms

5-25% of strains do not produce toxins and don t cause disease Toxin A 308 kd enter toxin and cytotoxin Chemo attractant for neutrophils Activator for macrophages and mast cells Toxin B 269 kd potent cytotoxin Disrupts the actin cytoskeleton Found to be a potent necrotizing enterotoxin Probably acts synergistically with toxin A

The indigenous microbiota of the gut constitutes a complex and poorly understood host defense system. Typically contains 10 11-10 12 bacteria per gram of feces. Four major groupings Bacteroides sp Bifidobacterium sp Clostridium coccoides group Clostridium leptum group En-masse they confer colonization resistance against C. difficile Depletion of monosaccharide components of mucin that serve as carbon sources for growth of C. difficile

The most common recognized cause of nosocomial diarrhea Incidence and severity increasing: A new strain has been identified that carries and additional toxin (iota toxin) C. difficile acquiring resistance to more antimicrobials Probably other as yet unrecognized reasons Frequency varies by institution Results in 3.6 excess hospital days, cost of $3,700/pt Readmissions for CDAD cost $128,000 per hospital per year Conservative estimate of US cost per year $1.1 billion

In healthy adults intestinal carriage rates of toxigenic C. difficile are 5% or less Carriage in healthy adults thought to be transient High prevalence in newborns- up to 60-70%- all asymptomatic In hospitalized patients colonization begins upon admission in patients given antimicrobials 13-20% within the first week 50% in patients hospitalized for more than 4 weeks Even relatively minute amounts of antimicrobials can predispose to colonization

Healthcare facilities-acquired infections in most cases, are the results of environmental contamination, and poor patient hygiene during hospitalization, and not how sick the patient were at the time of admission. A pessimist see the difficulty in every opportunity; an optimist see the opportunity in every difficulty.. W. Churchill

Antibiotics are the 2 nd most commonly used class of drug in the U.S. 8 billion dollars/year 200-300 million antibiotic prescriptions written/year, 25,000 tons of drug dispensed

45% for out-patient use 25-40% of all hospitalized patients receive antibiotics Patients use half of the antibiotics; agriculture and aquaculture account for the remaining half Antibiotics are societal drugs: Increase use of levofloxacin

Frequency of inadequate treatment (%) Pathogens Most Often Associated With Inappropriate Antimicrobial Treatment 20 18 16 14 12 10 8 6 4 2 0

Three critical events necessary for CDAD Disruption of the normal colonic micro flora by antimicrobials or other means Ingestion by the patient of a toxigenic strain of C. difficile and its arrival intact in the lower GI tract One or more additional requirements for developing invasive disease Advancing age Severe underlying disease of any kind Prolonged hospital stays Manipulation of the GI tract (NG tubes, enemas, surgery, motility altering drugs) Acid neutralizing drugs

Most common antimicrobials Clindamycin Ampicillin/amoxicillin Cephalosporins Fluoroquinolones Infrequent- Tetracyclines, macrolides, TMP/SMX Rare or never- IV aminoglycosides, metronidazole, vancomycin, bacitracin Chemotherapeutics with antibacterial activities Ifosfamide, carboplatin etoposide 8% incidence Others Mtx, 5FU, doxorubicin, cyclophosphamide Bowel preparation regimens

Asymptomatic colonization 2-5 or more X more common than clinical illness of any type Mild diarrhea, minimal discomfort Typical CDAD: Crampy abdominal pain Profuse diarrhea with mucoid, greenish watery stool with a characteristic odor Low grade fever and leukocytosis More severe disease with high fever, marked leukocytosis

Colitis can be throughout colon, but usually most severe in distal colon and rectum Localized right sided disease can present a diagnostic challenge Fulminant disease with ileus, toxic megacolon Uncommonly extraintestinal disease Reactive arthritis

Courtesy of Up to Date

Endoscopy looking for pseudo membranes Quick, and specific Pseudo membrane formation usually starts on the right side Pseudo membrane formation a late manifestation Culture Takes several days Need cytotoxic assay of organism after culture Immunoassays

Positive control Negative control Sensitivity: manufacturer states 95% compared to cytotoxic assay

General principles Whenever possible withdraw the offending antibiotic Use oral antimicrobials whenever possible Be patient- some improvement seen in first 2 days but mean time until resolution of diarrhea is 2-4 days. Don t call them nonresponders until 6 days of therapy Treat for 10 days Avoid antiperistaltic agents No role for test of cure assays

MIC 90 of 0.4 ug/ml vs. C. difficile 98% cure rate documented Well absorbed in the upper GI tract: in healthy volunteers fecal concentration of drug low to undetectable Bactericidal fecal concentrations achieved in the stool of patients with CDAD: fecal concentrations decrease as diarrhea improves Drug secreted directly across inflamed mucosa Decreased intestinal transit time with diarrhea decreases absorption

MIC 90 of 1.6 ug/ml Fecal concentrations of 2,000 to 5,000 ug/ml with po drug Cure rates 98-100% Second line therapy due to concerns of selecting for vancomycin resistant Enterococcus (VRE) No drug in GI tract when given IV Can be given by enema

Due to spores that germinate in gut after withdrawal of the antibiotic Happens in 20+ % of patients who initially respond. Increased risk in Age > 65 Increased severity of underlying disease Exposure to additional antibiotics after treatment Low serum IgG response to toxin A Half of relapses are actually re-infections Antibiotic resistance unlikely Most patients will respond to a second course of the same antimicrobial

No controlled studies, lots of anecdotes and personal favorite regimens Tapering courses of vancomycin or metronidazole Vancomycin plus rifampin Yogurt or other Lactobacillus preparations Saccharomyces boulardii plus antibiotics Intravenous immune globulin Cholestyramine with or without antimicrobials

Two main approaches Efforts directed at preventing horizontal spread including barrier methods, environmental cleaning Efforts to minimize the possibility that organism exposure will result in a clinical infection, using antimicrobial restriction and limiting overall use of antimicrobials

Contact Precautions including private room for all patients with diarrhea until C. difficile has been ruled out When should they come out of isolation? Since many healthy persons and persons without diarrhea who are in hospitals carry C. difficile in their intestinal tract there is no rationale for continuing isolation for patients who no longer have diarrhea, or to test them for carriage once the diarrhea has ceased.

Hand washing between all patient encounters Switch to alcohol based foams: is it contributing to C. difficile transmission? Environmental Cleaning Many common cleaners actually promote conversion of the vegetative form to the spore Bleach is the single most effective agent for spore killing